Efficacy of botulinum toxin type a for treating chronic low back pain: a systematic review and metanalysis
- 7 May 2026
- journal article
- review article
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 82 (6) , 143
Abstract
Background Chronic low back pain (CLBP) is a leading cause of pain and disability worldwide. Most cases are nonspecific, lacking a clear pathological cause, and management remains challenging. Botulinum toxin type A (BoNT-A), a neurotoxin that blocks acetylcholine release and reduces muscle hyperactivity, has been studied in CLBP with inconsistent results. This meta-analysis aimed to determine the efficacy of BoNT-A compared with placebo or saline in the management of nonspecific CLBP. Methods A comprehensive search of PubMed, Embase, Cochrane Library, and the WHO ICTRP databases was conducted for randomized controlled trials (RCTs) involving adults with nonspecific CLBP who received BoNT-A or placebo injections and were registered in PROSPERO (CRD42024559735). The primary outcome was pain response, defined as a ≥ 50% reduction in VAS score, while the secondary outcome was functional improvement. A random-effects model was used to calculate pooled risk ratios (RR) with 95% confidence intervals (CI). Results Five eligible RCTs involving 177 participants were analyzed. BoNT-A improved pain response compared with placebo [RR = 2.09, 95% CI: 1.11–3.95; p = 0.02; I2 = 62%]. Functional outcomes also favored BoNT-A [RR = 2.25, 95% CI: 1.09–4.67; p = 0.03; I2 = 69%]. Sensitivity analyses confirmed robustness. Exploratory meta-regression suggested a possible decrease in pain effect with longer follow-up, while functional outcomes showed no significant association; dose was not a significant moderator. Risk of bias was low in one trial, some concerns in three, and high in one. Certainty of evidence was low for both outcomes. Conclusion BoNT-A may improve pain and functional outcomes in nonspecific CLBP, although the certainty of evidence is low. Exploratory analyses suggested a possible decline in pain benefit over time, and safety data are limited. Larger, high-quality RCTs are needed to confirm these findings.Keywords
This publication has 34 references indexed in Scilit:
- The Efficacy and Safety of Botulinum Neurotoxin Type A in Treating Chronic Low Back Pain: A Systematic Review, Meta‐Analysis, Trial Sequential Analysis, and Meta‐RegressionEuropean journal of pain, 2025
- The Cochrane risk of bias assessment tool 2 (RoB 2) versus the original RoB: A perspective on the pros and consHealth Science Reports, 2024
- Botulinum neurotoxin A promotes functional recovery after peripheral nerve injury by increasing regeneration of myelinated fibersNeuroscience, 2017
- The State of US Health, 1990-2010JAMA, 2013
- Conversion ratio between Dysport and Botox in clinical practice: an overview of available evidenceNeurological Sciences, 2013
- GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tablesJournal of Clinical Epidemiology, 2011
- Distinctiveness of psychological obstacles to recovery in low back pain patients in primary carePain, 2010
- Pathophysiological model for chronic low back pain integrating connective tissue and nervous system mechanismsMedical Hypotheses, 2007
- Botulinum-A toxin in the treatment of craniocervical muscle spasms: Short- and long-term, local and systemic effectsSurvey of Ophthalmology, 1996
- Botulinum toxin in the treatment of myofascial pain syndromePain, 1994